If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,248.00    -42.00 (-1.83%)
Bid:
2,240.00
Ask:
2,256.00
Spread: 16.00 (0.714%)
Market Cap: £1.49b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

20 Sep 2011 15:07

RNS Number : 5938O
Genus PLC
20 September 2011
 

20 September 2011

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that of 117,359 ordinary shares of 10 pence each in the Company ("Ordinary Shares") which vested today in favour of Richard Wood, Chief Executive, under the Genus 2004 Performance Share Plan (the "Plan"), 117,359 Ordinary Shares were today sold on behalf of Richard Wood at a price of 1,000 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 45,856 Ordinary Shares which represents 0.08% of the issued share capital of the Company which is currently 60,239,150 Ordinary Shares.

 

Genus also announces that of 46,927 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 46,927 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 1,000 pence per Ordinary Share.

 

Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.01% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 41,061 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 31,061 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 1,000 pence per Ordinary Share.

 

Thomas Philip Acton's direct shareholding in the Company now stands at 31,104 Ordinary Shares which represents 0.06% of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415 conditional nil-cost options under the Plan.

 

Of 28,156 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 28,156 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 1,000 pence per Ordinary Share.

 

Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 61,462 conditional nil-cost options under the Plan.

 

Genus further announces that of 1,619 Ordinary Shares which vested today in favour of Bill Christianson, Chief Operating Officer, The Americas, under the Genus 2004 Executive Share Option Plan (the "ESOP"), 1,619 Ordinary Shares were today sold on behalf of Bill Christianson at a price of 1,000 pence per Ordinary Share.

 

Bill Christianson has no direct shareholding in the Company and is the beneficial owner of 56,953 conditional nil-cost options and 18,970 market value share options.

 

Of 6,673 Ordinary Shares which vested today in favour of David Crosby, Group Financial Controller, under the ESOP, 6,673 Ordinary Shares were today sold on behalf of David Crosby at a price of 1,000 pence per Ordinary Share.

 

David Crosby has no direct shareholding in the Company and is the beneficial owner of 53,843 conditional nil-cost options.

 

 

For further information please contact:

 

Cara Crichton

Assistant Company Secretary

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSURRSRANAKUAR
Date   Source Headline
13th Aug 200910:36 amRNSNotice of Results
31st Jul 20092:00 pmRNSBlocklisting Return
31st Jul 20092:00 pmRNSTotal Voting Rights
15th Jul 20092:00 pmRNSHolding(s) in Company
9th Jul 20097:00 amRNSPre-Close Trading Update
1st Jun 20092:00 pmRNSTotal Voting Rights
20th May 20092:00 pmRNSDirector/PDMR Shareholding
18th May 20092:00 pmRNSDirector/PDMR Shareholding
7th May 20097:00 amRNSBoard Appointment
1st May 20097:00 amRNSInterim Management Statement
30th Apr 20092:00 pmRNSTotal Voting Rights
14th Apr 20092:00 pmRNSHolding(s) in Company
6th Apr 20092:00 pmRNSAppointment of Broker & Adviser
3rd Mar 20092:00 pmRNSDirector's Share Options
26th Feb 20097:00 amRNSBoard Update
26th Feb 20097:00 amRNSInterim Results
20th Feb 20097:00 amRNSBusiness Expansion in China
5th Feb 200910:17 amRNSNotice of Results
30th Jan 20092:30 pmRNSBlocklisting Six Monthly Return
30th Jan 20092:30 pmRNSTotal Voting Rights
5th Jan 20097:00 amRNSAppointment of Brokers & Advisers
31st Dec 200812:40 pmRNSSecond Price Monitoring Extn
31st Dec 200812:37 pmRNSPrice Monitoring Extension
8th Dec 20084:33 pmRNSDirector/PDMR Shareholding
14th Nov 20084:04 pmRNSHolding(s) in Company
13th Nov 20083:06 pmRNSResult of AGM
13th Nov 20087:00 amRNSAGM & Interim Management Statement
27th Oct 20082:00 pmRNSHolding(s) in Company
17th Oct 20082:00 pmRNSAnnual Information Update
15th Oct 20082:30 pmRNSDirector/PDMR Shareholding
15th Oct 20082:00 pmRNSBoard Update
8th Oct 20084:47 pmRNSDirector/PDMR Shareholding
7th Oct 20082:00 pmRNSHolding(s) in Company
30th Sep 20082:08 pmRNSBlocklisting Interim Review
30th Sep 20082:00 pmRNSTotal Voting Rights
19th Sep 20081:37 pmRNSDirector/PDMR Shareholding
18th Sep 20087:00 amRNSUpdate on Strategy - China
16th Sep 20087:00 amRNSPreliminary Results
31st Jul 20084:00 pmRNSTotal Voting Rights
25th Jul 20084:00 pmRNSBlocklisting Interim Review
16th Jul 20087:00 amRNSPre-Close Trading Update
14th Jul 20082:00 pmRNSHolding(s) in Company
30th Jun 20084:30 pmRNSTotal Voting Rights
30th May 20084:00 pmRNSTotal Voting Rights
28th May 200812:06 pmRNSMerger Update
19th May 20083:51 pmRNSDirector/PDMR Shareholding
14th May 20084:00 pmRNSMerger Update
30th Apr 20084:00 pmRNSTotal Voting Rights
29th Apr 20087:00 amRNSInterim Management Statement
10th Apr 20084:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.